Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens

Oral Oncology

Volumn 46, Issue 11, 2010, Pages 818-821

  Massa, Elena ^a   Dess, Mariele ^a   Gaspardini, Giulio ^a   Saba, Federica ^a   Cherchi, Valeria ^a   Mantovani, Giovanni ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Cetuximab; Efficacy; Oral cancer; Progressive disease; Recurrent or metastatic SCCHN; Safety; Vinorelbine

Indexed keywords

CETUXIMAB; NAVELBINE;

ADULT; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; VINBLASTINE;

EID: 78049256716     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2010.08.013     Document Type: Article

References (21)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. J.B. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki, and S. Rottey Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 2008 1116 1127
3. X. Leon, R. Hitt, M. Constenla, A. Rocca, R. Stupp, and A.F. Kovacs A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy Clin Oncol (R Coll Radiol) 17 2005 418 424
4. J.B. Vermorken, R.S. Herbst, X. Leon, N. Amellal, and J. Baselga Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies Cancer 112 2008 2710 2719
5. M. Airoldi, L. Cattel, S. Marchionatti, V. Recalenda, F. Pedani, and V. Tagini Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results Am J Clin Oncol 26 2003 378 381 (Pubitemid 36962082)
6. J. Baselga, J.M. Trigo, J. Bourhis, J. Tortochaux, H. Cortes-Funes, and R. Hitt Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck J Clin Oncol 23 2005 5568 5577
7. R.S. Herbst, M. Arquette, D.M. Shin, K. Dicke, E.E. Vokes, and N. Azarnia Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck J Clin Oncol 23 2005 5578 5587
8. V. Gebbia, G. Mantovani, B. Agostara, A. Contu, A. Farris, and G. Colucci Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial Ann Oncol 6 1995 987 991
9. M. Degardin, J. Oliveira, L. Geoffrois, F. Rolland, J.P. Armand, and P. Bastit An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck Ann Oncol 9 1998 1103 1107
10. M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, and E.T. McFadden Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
11. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
12. National Cancer Institute - Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0 (CTCAE); 2006.
13. G. Numico, and M. Merlano Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer Ann Oncol 13 2002 331 333
14. A. Iop, G. Cartei, and A. Isaia Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil Ann Oncol 9 1998 225 227
15. V. Gebbia, R. Valenza, A. Testa, N. Borsellino, G. Cannata, and S. Restivo Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck ORL J Otorhinolaryngol Relat Spec 56 1994 279 282
16. Porta CBS, Patruno E, et al. Single-agent vinorelbine (VRB) as second-line treatment for advanced or recurrent squamous-cell carcinoma of the head and neck (SCCHN) [abstract]. Proc Am Soc Clin Oncol 2001;20 (part 2) [Abstract # 2537:197b].
17. Kies MSAM, Nabell L, et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy [abstract]. Proc Am Soc Clin Oncol 2002;21 (part 1) [Abstract # 925:232a].
18. B. Burtness, M.A. Goldwasser, W. Flood, B. Mattar, and A.A. Forastiere Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study J Clin Oncol 23 2005 8646 8654
19. Trigo J HR, Koralewski P, et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study [abstract]. J Clin Oncol, 2004 ASCO annual meeting proceedings (Post-Meeting Edition) 2004;22(14S) [Abstract # 5502:487].
20. J.B. Vermorken, J. Trigo, R. Hitt, P. Koralewski, E. Diaz-Rubio, and F. Rolland Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy J Clin Oncol 25 2007 2171 2177
21. Baselga J TJ, Bourhis J, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen [abstract]. Proc Am Soc Clin Oncol 2002;21 (part 1). [Abstract # 900:226a].